LUMILIXIMAB TREATMENT RESULTS IN INCREASES IN SERUM CD23 BUT NO MODULATION OF MEMBRANE CD23 IN RELAPSED CLL PATIENTS

被引：0
|
作者：
Harris, S. G. [1 ]
Ranuio, J. V. [1 ]
Estrellado, A. [1 ]
Hughes, S. G. [1 ]
Tangri, S. [1 ]
机构：
[1] Biogen Idec Inc, San Diego, CA USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1546
引用
收藏
页码：599 / 599
页数：1
相关论文
共 50 条
  • [1] Saturation of the CD23 receptor by lumiliximab in relapsed chronic lymphocytic leukemia patients
    Harris, Sarah
    Estrellado, Annalee
    Subramanyam, Meena
    Cesano, Alessandra
    Ranuio, Julie
    Mu, Hua
    Tangri, Shabnam
    CANCER RESEARCH, 2008, 68 (09)
  • [2] CD23 AND IMMUNE MODULATION
    GORDON, J
    LIU, YJ
    MACLENNAN, ICM
    FLORESROMO, L
    SHIELDS, J
    BONNEFOY, JY
    IMMUNOLOGY TODAY, 1991, 12 (06): : 206 - 206
  • [3] The diagnostic role of CD23 in CLL and MCL
    Barna, G.
    Matolcsy, A.
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2007, 72B (02) : 145 - 145
  • [4] CD23 ANTIGEN EXPRESSION IN CLL - REPLY
    DADMARZ, R
    CAWLEY, JC
    BRITISH JOURNAL OF HAEMATOLOGY, 1989, 72 (04) : 598 - 598
  • [5] Soluble CD23 levels increase following lumiliximab dosing in relapsed chronic lymphocytic leukemia patients
    Harris, Sarah
    Woodworth, James
    Ranuio-Kelley, Julie
    Estrellado, Annalee
    Cesano, Alessandra
    Mu, Hua
    Tangri, Shabnam
    CANCER RESEARCH, 2008, 68 (09)
  • [6] Clinical activity of lumiliximab and FCR does not correlate with baseline levels or modulation of serum CD23, beta-2 microglobulin, and CLL cell levels in CLL patients
    Harris, S.
    Ranuio-Kelley, J.
    Estrellado, A.
    Byrd, J.
    O'Brien, S.
    Kipps, T.
    Cesano, A.
    Mu, H.
    Tangri, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 160 - 160
  • [7] CD23 AND EOSINOPHILS
    CAPRON, M
    TRUONG, MJ
    RESEARCH IN IMMUNOLOGY, 1992, 143 (04): : 442 - 444
  • [8] SERUM-SOLUBLE CD23 IN PATIENTS WITH HYPOGAMMAGLOBULINEMIA
    BANSAL, AS
    HAENEY, MR
    COCHRANE, S
    PUMPHREY, RSH
    GREEN, LM
    BHAVNANI, M
    WILSON, PB
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 97 (02): : 239 - 241
  • [9] Clinical activity of the anti-CD23 antibody lumiliximab is independent of CD23, CD38 and ZAP 70 expression level by CLL Bcells
    Harris, Sarah
    Ranuio, Julie
    Estrellado, Annalee
    Mu, Hua
    Cesano, Alessandra
    Tangri, Shabnam
    CANCER RESEARCH, 2008, 68 (09)
  • [10] SOLUBLE CD23 IN THE SERUM OF CHILDREN WITH ASCARIASIS
    HAMADA, A
    WATANABE, N
    YANAGIHARA, Y
    BARBOSA, I
    TATENO, S
    KOBAYASHI, A
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1991, 85 (04) : 529 - 530
12345